Biogen Inc., of Cambridge, Mass., appointed Craig Schneier executive vice president, human resources.
Cellular Genomics Inc., of Branford, Conn., named Thomas Gerson chief financial officer and promoted Mark Velleca to vice president of research and preclinical development.
Chronogen Inc., of Montreal, appointed Pierre Cantin to its board.
Embrex Inc., of Research Triangle Park, N.C., elected David Castaldi to its board.
Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., appointed Clive Meanwell to its board.
Gentris Corp., of Research Triangle Park, N.C., added Gary Pace as vice president for corporate development and legal affairs, and promoted David Gessner to vice president for business development and marketing and Scott Clark to executive director of laboratory services.
Guava Technologies Inc., of Hayward, Calif., appointed Paul Kinnon vice president of sales and marketing.
ImClone Systems Inc., of New York, promoted Clifford Saffron to senior vice president, general counsel.
LION bioscience AG, of Heidelberg, Germany, appointed Reiner Doelle vice president for global software development.
Lorus Therapeutics Inc., of Toronto, appointed Robert Capizzi as a director, retained Bruce Rowlands as senior adviser, and promoted Ping Wei to comptroller.
Maxim Pharmaceuticals Inc., of San Diego, nominated Robert Zerbe as an independent member of its board.
Montreux Equity Partners, of Menlo Park, Calif., added Howard Palefsky as general partner.
Nanosys Inc., of Palo Alto, Calif., added Louis Brus as scientific adviser.
Norak Biosciences Inc., of Research Triangle Park, N.C., promoted Carson Loomis to senior vice president, research and Terry Willard to executive vice president.
Novacea Inc., of South San Francisco, appointed Robert Capizzi vice president, medical affairs.
Pheromone Sciences Corp., of Toronto, appointed Jim Wooder to its board.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., elected Arthur Ryan to its board.
Samaritan Pharmaceuticals Inc., of Las Vegas, added Julio Garcia to its scientific advisory board.
Sequenom Inc., of San Diego, elected Harry Hixson to its board.
TargeGen Inc., of San Diego, appointed David McClure vice president of regulatory affairs and drug development.
Vela Pharmaceuticals Inc., of Lawrenceville, N.J., hired Karen Correnti as senior director of intellectual property.